August 17, 2021 – Page 2

Helicopter Market Share, COVID-19 Impact Analysis [2021-2028] | Global Helicopter Industry Expected to Hit USD 69.20 Billion at 4.1% CAGR during Forecast Period, Says Fortune Business Insights™

Written by Customer Service on August 17, 2021. Posted in Mergers And Acquisitions.

Top 11 companies profiled in helicopter market are Airbus SAS (the Netherlands), Bell Helicopter Textron (The U.S.), The Boeing Company (The U.S.), Leonardo SPA (Italy), Lockheed Martin Corporation (The U.S.), Russian Helicopters, JSC (Russia), Kawasaki Heavy Industries, Ltd. (Japan), M.D. Helicopters, Inc. (The U.S.), Korea Aerospace Industries, Ltd. (South Korea), Hindustan Aeronautics Limited (HAL) (India), and Robinson Helicopter Company (The U.S.) Pune, India, Aug. 17, 2021 (GLOBE NEWSWIRE) — The global helicopter market share is expected to showcase exponential growth by reaching USD 69.20 billion by 2028 while exhibiting a CAGR of 4.1% between 2021 and 2028. This information is published by Fortune Business Insights in its report, titled “Helicopter Market, 2021-2028.” The report further mentions that the market stood at...

Webster, Sterling Stockholders Approve Merger

Written by Customer Service on August 17, 2021. Posted in Mergers And Acquisitions.

WATERBURY, Conn. and PEARL RIVER, N.Y., Aug. 17, 2021 (GLOBE NEWSWIRE) — Webster Financial Corporation (NYSE: WBS) (“Webster”) and Sterling Bancorp (NYSE: STL) (“Sterling”) jointly announced that each company’s stockholders have approved the proposed merger between Webster and Sterling at their respective special meetings of stockholders held today. The final voting results on the proposals voted on at the special meetings will be set forth in the companies’ separate Form 8-Ks filed with the U.S. Securities and Exchange Commission (the “SEC”) after certification by each company’s inspector of election. “Today’s stockholder approval marks a key step in completing the merger of Webster and Sterling,” said John R. Ciulla, Chairman, President & CEO of Webster. “I am very pleased that our stockholders overwhelmingly support bringing...

Mudrick Capital Acquisition Corporation II Reminds Stockholders to Vote in Favor of Business Combination With Topps

Written by Customer Service on August 17, 2021. Posted in Mergers And Acquisitions.

Special Meeting is scheduled for August 25, 2021 at 10:00 a.m. Eastern Time. Stockholders who held MUDS shares as of the close of business on June 30, 2021, the record date for the Special Meeting, are encouraged to vote as soon as possible. If you need assistance voting your shares, please contact MUDS’ proxy solicitor D.F. King & Co., Inc., by telephone at (800) 549-6864 or collect at (212) 269-5550 or email at MUDS@dfking.com. NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) — Mudrick Capital Acquisition Corporation II (“MUDS” or the “Company”) (Nasdaq: MUDS) today reminded stockholders to vote in favor of the previously announced business combination (the “Business Combination Proposal”) with The Topps Company, Inc. (“Topps”). The special meeting in lieu of the 2021 annual meeting of stockholders (the “Special Meeting”)...

Argentine Court acquits Tenaris’s CEO and Chairman in the Notebooks Case

Written by Customer Service on August 17, 2021. Posted in Public Companies.

LUXEMBOURG, Aug. 17, 2021 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and MTA Italy: TEN) has been informed that the first-instance judge in charge of the Notebooks Case acquitted Tenaris’s Chairman and CEO Paolo Rocca of all charges brought against him in the case. In its decision, the first-instance judge stated that Mr. Rocca’s involvement in the Notebooks Case’s judicial proceedings does not affect his good name and honor in any way. The first-instance judge’s decision concerning Mr. Rocca was not appealed by either the prosecutor or the government unit prosecuting economic crimes (UIF). Tenaris is a leading global supplier of steel tubes and related services for the world’s energy industry and certain other industrial applications. Giovanni SardagnaTenaris 1-888-300-5432www.tenaris.com

ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units

Written by Customer Service on August 17, 2021. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has filed today a preliminary prospectus supplement (the “Supplement”) to its final short form base shelf prospectus dated June 30, 2021 (the “Base Prospectus”) in connection with a proposed commercially reasonable efforts public offering of units (the “Units”) for gross proceeds to the Company of up to US$15,000,000, exclusive of the Agent’s Option (as defined herein) (the “Offering”). Each Unit consists of one common share of the Company (a “Common Share”) and one...

TOFUTTI ANNOUNCES RESULTS FOR THIRTEEN AND TWENTY-SIX WEEKS ENDED JULY 3, 2021

Written by Customer Service on August 17, 2021. Posted in Public Companies.

Cranford, New Jersey, Aug. 17, 2021 (GLOBE NEWSWIRE) — TOFUTTI BRANDS INC. (OTCQB Symbol: TOFB) today announced its results for the thirteen and twenty-six week periods ended July 3, 2021. Tofutti Brands reported net sales for the thirteen weeks ended July 3, 2021 of $3,027,000 compared to net sales of $3,243,000 for the thirteen weeks ended June 27, 2020. Sales of vegan cheese products decreased slightly to $2,497,000 in the 2021 period from $2,547,000 in the 2020 period due to manufacturing delays at our co-packing facility for vegan cheese slices, which have since been resolved. Frozen dessert and frozen food products sales decreased by $166,000 to $530,000 in the thirteen weeks ended July 3, 2021 from $696,000 for the thirteen weeks ended June 27, 2020. The decrease in frozen dessert sales was due to the discontinuance of Yours...

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

Written by Customer Service on August 17, 2021. Posted in Public Companies.

Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSK JEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April 2021 $20MM Milestone Payment Earned by AnaptysBio Upon Second JEMPERLI FDA Approval in Addition to $40MM Already Earned Upon Prior Regulatory Milestones During 2021 Additional $15MM and $165MM Milestones Due Upon Achievement of JEMPERLI Regulatory and Commercial Milestones, Respectively AnaptysBio Due to Receive 8% to 25% Royalty on Global Net Sales of JEMPERLI SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications,...

Innergex and Hydro-Québec Announce the First Joint Acquisition Under Their Strategic Alliance and Concurrent Bought Deal Equity Financing and Private Placement by Innergex

Written by Customer Service on August 17, 2021. Posted in Mergers And Acquisitions.

Acquisition of the 60 MW Curtis Palmer run-of-river hydroelectric portfolio in the state of New York Leverages the Strategic Alliance between Innergex and Hydro-Québec via a joint 50-50 acquisition Expands Innergex’s U.S. presence with entry in the attractive New York renewables market PPA with Niagara Mohawk Power Corporation (A3 / BBB+) expected to contribute US$19.7 million ($24.6 million) of average annual Free Cash Flow1 to Innergex without any debt financing Innergex expects double-digit annual Free Cash Flow per Share1 accretion and greater than 10% reduction in Payout Ratio1 in the first full year of ownership Innergex to benefit from a $175.0 million bought deal common equity financing and $43.5 million concurrent private placement with Hydro-Québec THIS MEDIA RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR...

Atico Reports Financial Results for Second Quarter of 2021

Written by Customer Service on August 17, 2021. Posted in Earnings Releases And Operating Results.

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, Aug. 17, 2021 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the three months ended June 30, 2021 (“Q2-2021”), posting income from mining operations of $4.9 million and a net income of $0.6 million. Fernando E. Ganoza, CEO and Director, commented, “Similarly to the previous quarter, the challenging situation in country and severe weather conditions resulted in operational setbacks, a slight loss of production and an increase in cash cost. The costs were partially mitigated by higher realized metal prices leading to a cash margin of $3.23 per pound of payable copper. Despite these challenges, the Company closed the quarter showing a strong cash position...

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

Written by Customer Service on August 17, 2021. Posted in Earnings Releases And Operating Results.

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the second quarter 2021. “During the second quarter 2021, we continued to make significant clinical progress advancing our IL-2 based CUE-100 series, represented by the Phase 1a/1b monotherapy trial of CUE-101 and combination-therapy trial with KEYTRUDA® (pembrolizumab). In addition, we have continued with the development and expansion of our pipeline programs and technology platforms, and also enhanced our capital resources,” said Daniel Passeri, chief executive officer of Cue Biopharma. “Importantly, we recently reported...

Day: August 17, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice